Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maha Ayyoub

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
JCI Insight|December 17, 2020
PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cellsCamille-Charlotte Balança, Anna Salvioni, Clara-Maria Scarlata, et al.
Journal for Immunotherapy of Cancer|August 4, 2025
HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancerPaola Bonaventura, Audrey Page, Olivier Tabone, et al.
NPJ Precision Oncology|April 9, 2026
Terminal T-cell exhaustion predicts tumor control independent of immunotherapy in ovarian cancerAnna Salvioni, Marie Michelas, Mathilde Del, et al.
Cancer Immunology Research|April 17, 2020
Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial MalignanciesCamille-Charlotte Balança, Clara-Maria Scarlata, Marie Michelas, et al.
Immunity|October 14, 2020
Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8<sup>+</sup> T Cell Anti-tumor Functions and Limits the Efficacy of Cancer ImmunotherapyMarianne Weulersse, Assia Asrir, Andrea C Pichler, et al.
Science (New York, N.Y.)|August 22, 2020
Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophageAurélie Fluckiger, Romain Daillère, Mohamed Sassi, et al.
Oncoimmunology|July 3, 2015
Consensus nomenclature for CD8<sup>+</sup> T cell phenotypes in cancerLionel Apetoh, Mark J Smyth, Charles G Drake, et al.
Oncotarget|December 25, 2014
Classification of current anticancer immunotherapiesLorenzo Galluzzi, Erika Vacchelli, José-Manuel Bravo-San Pedro, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
JCI Insight|December 17, 2020
PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cellsCamille-Charlotte Balança, Anna Salvioni, Clara-Maria Scarlata, et al.
Journal for Immunotherapy of Cancer|August 4, 2025
HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancerPaola Bonaventura, Audrey Page, Olivier Tabone, et al.
NPJ Precision Oncology|April 9, 2026
Terminal T-cell exhaustion predicts tumor control independent of immunotherapy in ovarian cancerAnna Salvioni, Marie Michelas, Mathilde Del, et al.
Cancer Immunology Research|April 17, 2020
Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial MalignanciesCamille-Charlotte Balança, Clara-Maria Scarlata, Marie Michelas, et al.
Immunity|October 14, 2020
Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8<sup>+</sup> T Cell Anti-tumor Functions and Limits the Efficacy of Cancer ImmunotherapyMarianne Weulersse, Assia Asrir, Andrea C Pichler, et al.
Science (New York, N.Y.)|August 22, 2020
Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophageAurélie Fluckiger, Romain Daillère, Mohamed Sassi, et al.
Oncoimmunology|July 3, 2015
Consensus nomenclature for CD8<sup>+</sup> T cell phenotypes in cancerLionel Apetoh, Mark J Smyth, Charles G Drake, et al.
Oncotarget|December 25, 2014
Classification of current anticancer immunotherapiesLorenzo Galluzzi, Erika Vacchelli, José-Manuel Bravo-San Pedro, et al.
Pageof 9